long intergenic non-protein coding RNA 431Genealiases: []
Q-omics provides the consensus-scored LINC00431 profile across patient tissues and cancer cell-line models. LINC00431 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, LINC00431 is differentially expressed in 6, with the highest sampling consensus in UCEC. Additionally, LINC00431 RNA expression shows 4,836 significant pathway-activity associations, with the highest sampling consensus in UCEC. Together, these results highlight LUAD, and UCEC as cancer lineages where LINC00431 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00431 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00431 survival associations across molecular data types. LINC00431 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00431 RNA expression–survival associations across cancer types. High LINC00431 expression shows unfavorable associations in LUAD, ACC, DLBC, LIHC, KICH and STAD. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for LINC00431 RNA expression.
This table summarizes LINC00431 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00431. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00431 shows higher tumor expression in UCEC, HNSC, PAAD, STAD, COAD and LUAD. The UCEC box plot shows higher LINC00431 RNA expression in tumor versus normal tissue (log2 FC = +0.605, t-test p = .007).
This table shows molecular features associated with LINC00431 in patient tissues and cancer cell lines. In patient samples, LINC00431 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
